Abstract
Despite timely reperfusion and subsequent optimal postinfarct pharmacotherapy and device-based treatment, the outcome in patients with severe myocardial infarction remains unfavourable. Myocardial salvage is incomplete, resulting in adverse left ventricular remodeling with concomitant morbidity and mortality. The combined risk of recurrent myocardial infarction, death or readmission for heart failure amounts to 25 % within the first year, highlighting the need for additional treatment strategies. Recent and rapidly evolving insights in cardiac biology, recognizing endogenous repair capabilities of the adult human heart, paved the path towards progenitor or stem cell based cardiac protection and repair strategies following ischemic injury. We critically report on the major randomized controlled clinical trials published so far concerning intracoronary transfer of autologous bone marrow cells in the setting of acute myocardial infarction. Moreover, underlying mechanisms, practical aspects, remaining questions and future challenges are highlighted. Taken together, these trials confirm the safety and feasibility of intracoronary progenitor cell transfer in the setting of myocardial infarction. Efficacy data suggests its potential to improve left ventricular function recovery beyond current state of the art therapy, but results are mixed, modest at best and do not support true cardiomyogenesis. Hence, due to its complexity, costs and remaining uncertainties, it is still too early to implement progenitor cell therapy in its current form in standard treatment strategies for ischemic heart disease. Future studies on strategies for cardiomyocyte regeneration in combination with myocardial protection are needed.
Keywords: Myocardial infarction, ischemic heart disease, stem cell, progenitor cell, bone marrow, regenerative cardiology, phenotype, cytokines, erythropoietin, clinical trials
Current Pharmaceutical Design
Title: Stem Cell Therapy for the Treatment of Myocardial Infarction
Volume: 17 Issue: 30
Author(s): D. F. Dauwe and S. P. Janssens
Affiliation:
Keywords: Myocardial infarction, ischemic heart disease, stem cell, progenitor cell, bone marrow, regenerative cardiology, phenotype, cytokines, erythropoietin, clinical trials
Abstract: Despite timely reperfusion and subsequent optimal postinfarct pharmacotherapy and device-based treatment, the outcome in patients with severe myocardial infarction remains unfavourable. Myocardial salvage is incomplete, resulting in adverse left ventricular remodeling with concomitant morbidity and mortality. The combined risk of recurrent myocardial infarction, death or readmission for heart failure amounts to 25 % within the first year, highlighting the need for additional treatment strategies. Recent and rapidly evolving insights in cardiac biology, recognizing endogenous repair capabilities of the adult human heart, paved the path towards progenitor or stem cell based cardiac protection and repair strategies following ischemic injury. We critically report on the major randomized controlled clinical trials published so far concerning intracoronary transfer of autologous bone marrow cells in the setting of acute myocardial infarction. Moreover, underlying mechanisms, practical aspects, remaining questions and future challenges are highlighted. Taken together, these trials confirm the safety and feasibility of intracoronary progenitor cell transfer in the setting of myocardial infarction. Efficacy data suggests its potential to improve left ventricular function recovery beyond current state of the art therapy, but results are mixed, modest at best and do not support true cardiomyogenesis. Hence, due to its complexity, costs and remaining uncertainties, it is still too early to implement progenitor cell therapy in its current form in standard treatment strategies for ischemic heart disease. Future studies on strategies for cardiomyocyte regeneration in combination with myocardial protection are needed.
Export Options
About this article
Cite this article as:
F. Dauwe D. and P. Janssens S., Stem Cell Therapy for the Treatment of Myocardial Infarction, Current Pharmaceutical Design 2011; 17 (30) . https://dx.doi.org/10.2174/138161211797904208
DOI https://dx.doi.org/10.2174/138161211797904208 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Evolving Roles of Nuclear Cardiology
Current Cardiology Reviews T-Cell-Mediated Signalling in Immune, Inflammatory and Angiogenic Processes: The Cascade of Events Leading to Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy There is no Failure, Only Discovery—the Year Ahead for CARving New Paths
Current Alzheimer Research Olive Oil-related Anti-inflammatory Effects on Atherosclerosis: Potential Clinical Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Effects of Thiazolidinediones on Coronary Artery Disease: Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Molecular Targets and Natural Compounds in Drug Development for the Treatment of Inflammatory Pain
Current Drug Targets Insights from Exercise-induced Cardioprotection-from Clinical Application to Basic Research
Current Pharmaceutical Design Meet Our Editorial Board Member:
Current Vascular Pharmacology Capacity Building in Genomics Medicine and Molecular Diagnostics: The Case of Sri Lanka
Current Pharmacogenomics and Personalized Medicine Pharmacological Approaches in the Treatment of Atrial Fibrillation
Current Medicinal Chemistry Ubiquitin and ubiquitin-like proteins in cardiac disease and protection
Current Drug Targets Study of Parasitic Infections, Cancer, and other Diseases with Mass-Spectrometry and Quantitative Proteome-Disease Relationships
Current Proteomics The Potential Application of Biomaterials in Cardiac Stem Cell Therapy
Current Medicinal Chemistry Leptin and Vascular Smooth Muscle Cells
Current Pharmaceutical Design Green Synthesis of Zinc Oxide Nanoparticles (ZnO NPs) using Aqueous Extract of <i>Tagetes Erecta</i> flower and Evaluation of its Antioxidant, Antimicrobial, and Cytotoxic activities on HeLa cell line.
Current Biotechnology Modulation of Neuro-Inflammation and Vascular Response by Oxidative Stress Following Cerebral Ischemia-Reperfusion Injury
Current Medicinal Chemistry Adhatoda vasica Nees: Phytochemical and Pharmacological Profile
The Natural Products Journal Formulated Squalene for Food Related Applications
Recent Patents on Food, Nutrition & Agriculture Heart Failure in Chronic Myocarditis: A Role for microRNAs?
Current Genomics